RecruitingNot ApplicableNCT06251323

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)


Sponsor

Stanford University

Enrollment

119,680 participants

Start Date

Sep 30, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Sixteen institutions will be selected from a HRSA uniform data system and have data collected for up to 3 years. Eight institutions will begin the iPATH practice transformation during year one, the other eight institutions will begin iPATH in year two. FQHC administrators, clinicians and staff will be enrolled to participate in the iPATH transformation in their clinic and will participate in qualitative interviews. Patient HbA1c data from the clinics will be collected for comparative data analysis during each year of the study.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Two largest clinic sites in multi-clinic FQHCs operating in or near Massachusetts, Ohio, California, Puerto Rico
  • We will prioritize FQHCs performing in the lower half of the distribution for A1c control, as these FQHCs have greater room for improvement.

Exclusion Criteria3

  • FQHCs that have a patient population comprised of more than 80% children
  • FQHCs that have a patient population multiplied by the FQHC's diabetes prevalence in the lowest 10% of all the clinics
  • FQHCs that have fewer than 5,000 or more than 50,000 patients.

Interventions

OTHERiPATH implementation approach

A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy.


Locations(4)

Board of Trustees of the Leland Stanford Junior University

Stanford, California, United States

President and Fellows of Harvard College, T.H. Chan School

Boston, Massachusetts, United States

The Ohio State University

Columbus, Ohio, United States

Impactivo, LLC.

San Juan, Puerto Rico, Puerto Rico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06251323


Related Trials